Stephens!DM,!Li!H,!LeBlanc!ML,!Puvvada!SD,!Persky!D,!Friedberg!JW,!Smith!SM.!
J!Clin!Oncol.!2016!Sep!1;34(25):2997>3004.!doi:!10.1200/JCO.2015.65.4582.!Epub!2016!Jul!5.!
!
International! prognostic! indices! in! diffuse! large! B>cell! lymphoma:! a! comparison! of! IPI,! R>IPI,! and!
NCCN>IPI.!
Ruppert!AS,!Dixon!JG,!Salles!G,!Wall!A,!Cunningham!D,!Poeschel!V,!Haioun!C,!Tilly!H,!Ghesquieres!H,!
Ziepert!M,!Flament!J,!Flowers!C,!Shi!Q,!Schmitz!N.!
Blood.!2020!Jun!4;135(23):2041>2048.!doi:!10.1182/blood.2019002729.!
!
Prognostic! Significance! of! MYC! Rearrangement! and! Translocation! Partner! in! Diffuse! Large! B>Cell!
Lymphoma:!A!Study!by!the!Lunenburg!Lymphoma!Biomarker!Consortium.!
Rosenwald!A,!Bens!S,!Advani!R,!Barrans!S,!Copie>Bergman!C,!Elsensohn!MH,!Natkunam!Y,!Calaminici!
M,!Sander!B,!Baia!M,!Smith!A,!Painter!D,!Pham!L,!Zhao!S,!Ziepert!M,!Jordanova!ES,!Molina!TJ,!Kersten!
MJ,! Kimby! E,! Klapper!W,! Raemaekers! J,! Schmitz! N,! Jardin! F,! Stevens!WBC,! Hoster! E,! Hagenbeek! A,!
Gribben! JG,! Siebert! R,! Gascoyne! RD,! Scott! DW,! Gaulard! P,! Salles! G,! Burton! C,! de! Jong! D,! Sehn! LH,!
Maucort>Boulch!D.!
J!Clin!Oncol.!2019!Dec!10;37(35):3359>3368.!doi:!10.1200/JCO.19.00743.!Epub!2019!Sep!9.!
!
Intensified! chemotherapy! with! ACVBP! plus! rituximab! versus! standard! CHOP! plus! rituximab! for! the!
treatment!of!diffuse!large!B>cell!lymphoma!(LNH03>2B):!an!open>label!randomised!phase!3!trial.!
Récher!C,!Coiffier!B,!Haioun!C,!Molina!TJ,!Fermé!C,!Casasnovas!O,!Thiéblemont!C,!Bosly!A,!Laurent!G,!
Morschhauser! F,! Ghesquières! H,! Jardin! F,! Bologna! S,! Fruchart! C,! Corront! B,! Gabarre! J,! Bonnet! C,!
Janvier!M,!Canioni!D,!Jais!JP,!Salles!G,!Tilly!H;!Groupe!d'Etude!des!Lymphomes!de!l'Adulte.!
Lancet.!2011!Nov!26;378(9806):1858>67.!doi:!10.1016/S0140>6736(11)61040>4.!
!
Four! versus! six! cycles! of! CHOP! chemotherapy! in! combination! with! six! applications! of! rituximab! in!
patients!with!aggressive!B>cell!lymphoma!with!favourable!prognosis!(FLYER):!a!randomised,!phase!3,!
non>inferiority!trial.!
Poeschel!V,!Held!G,!Ziepert!M,!Witzens>Harig!M,!Holte!H,!Thurner!L,!Borchmann!P,!Viardot!A,!Soekler!
M,! Keller! U,! Schmidt! C,! Truemper! L,! Mahlberg! R,! Marks! R,! Hoeffkes! HG,! Metzner! B,! Dierlamm! J,!
Frickhofen! N,! Haenel! M,! Neubauer! A,! Kneba! M,! Merli! F,! Tucci! A,! de! Nully! Brown! P,! Federico! M,!
Lengfelder!E,!di!Rocco!A,!Trappe!R,!Rosenwald!A,!Berdel!C,!Maisenhoelder!M,!Shpilberg!O,!Amam!J,!
Christofyllakis!K,!Hartmann!F,!Murawski!N,!Stilgenbauer!S,!Nickelsen!M,!Wulf!G,!Glass!B,!Schmitz!N,!
Altmann!B,!Loeffler!M,!Pfreundschuh!M;!FLYER!Trial!Investigators;!German!Lymphoma!Alliance.!
Lancet.!2019!Dec!21;394(10216):2271>2281.!doi:!10.1016/S0140>6736(19)33008>9.!
!
Positron!Emission!Tomography>Directed!Therapy!for!Patients!With!Limited>Stage!Diffuse!Large!B>Cell!
Lymphoma:!Results!of!Intergroup!National!Clinical!Trials!Network!Study!S1001.!
Persky!DO,!Li!H,!Stephens!DM,!Park!SI,!Bartlett!NL,!Swinnen!LJ,!Barr!PM,!Winegarden!JD!3rd,!Constine!
LS,!Fitzgerald!TJ,!Leonard!JP,!Kahl!BS,!LeBlanc!ML,!Song!JY,!Fisher!RI,!Rimsza!LM,!Smith!SM,!Miller!TP,!
Friedberg!JW.!
J!Clin!Oncol.!2020!Sep!10;38(26):3003>3011.!doi:!10.1200/JCO.20.00999.!Epub!2020!Jul!13.!
!
The!prevention!of!central!nervous!system!relapse!in!diffuse!large!B>cell!lymphoma:!a!British!Society!
for!Haematology!good!practice!paper.!
McKay!P,!Wilson!MR,!Chaganti!S,!Smith!J,!Fox!CP,!Cwynarski!K;!British!Society!of!Haematology.!
Br!J!Haematol.!2020!Sep;190(5):708>714.!doi:!10.1111/bjh.16866.!Epub!2020!Jul!15.!
!
Dose>adjusted! EPOCH>R! (etoposide,! prednisone,! vincristine,! cyclophosphamide,! doxorubicin,! and!
rituximab)! in! untreated! aggressive! diffuse! large! B>cell! lymphoma! with! MYC! rearrangement:! a!
prospective,!multicentre,!single>arm!phase!2!study.!
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES